• BioArctic partner Eisai presented AAIC 2026 data indicating Leqembi subcutaneous autoinjector could match IV efficacy, safety in early Alzheimer’s disease.
• Once-weekly 500 mg SC dosing showed bioequivalence to IV initiation, with 104% exposure ratio (90% CI: 99.1%-109%).
• Data linked amyloid reduction, CDR-SB outcomes, ARIA-E risk to drug exposure rather than administration route.
• Safety broadly aligned with IV; injection-site reactions mainly local; anti-drug antibodies 1.4% with no neutralizing antibodies observed.
• Findings support a fully subcutaneous pathway, including switching between IV and SC, potentially expanding access via at-home administration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via PR Newswire (Ref. ID: HS02577) on July 13, 2026, and is solely responsible for the information contained therein.